This collective evidence prompted Dr. Ryu to propose that SETDB1-mediated H3K9me3 might contribute to the pathology of HD, and small compounds selectively targeting SETDB1 could serve as a new strategy for the treatment of HD. The gene discussed is SETDB1; the disease is Huntington disease.